Radiopharm Theranostics received a positive recommendation from its Data Safety and Monitoring Committee to escalate the dose of its radiotherapeutic drug 177Lu-RAD202 to 130mCi in the ongoing Phase 1 HEAT trial targeting HER2-positive advanced solid tumors. This advancement reflects a favorable safety profile and allows the company to accelerate dose escalation, aiming to complete Phase 1 by the end of 2026. The trial is conducted across Australian clinical centers and builds on earlier positive safety and biodistribution results in HER2-positive breast cancer patients. This progress is significant as RAD202 targets a validated cancer marker, potentially offering new treatment options for patients with advanced solid tumors.
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
